ArticleClinical and experimental nephrology2026
Discrepancy between cystatin C-based and creatinine-based eGFR predicts all-cause mortality in a community-based population: the Takahata study.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between extracellular-to-total body water ratio and eGFR decline in diabetic kidney disease: a longitudinal cohort study.Clinical and experimental nephrology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiscrepancies between the cystatin C-based estimated glomerular filtration rate (eGFRcys) and the creatinine-based estimated glomerular filtration rate (eGFRcr) have been linked to adverse outcomes in Western populations. However, their prognostic significance in community-dwelling Japanese individuals remains unclear. Therefore, we conducted a prospective cohort study to evaluate this association.
methodsWe analyzed data from 1308 participants who underwent simultaneous measurements of serum creatinine and cystatin C levels between 2004 and 2006, with a median follow-up of 18.5 years. The discrepancy (eGFRdiff = eGFRcys - eGFRcr) was categorized into three groups: a low group (< - 10 mL/min/1.73 m
resultsDuring the follow-up period, 386 participants (29.5%) died, including 120 cardiovascular-related deaths. Compared with the reference group, individuals in the eGFRdiff < - 10 group exhibited a significantly higher risk of all-cause mortality (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.10-1.80), whereas those in the ≥ 10 group showed a lower risk (HR: 0.56; 95% CI: 0.33-0.97). No significant association was observed with cardiovascular mortality. Incorporating eGFRdiff into the baseline models improved discrimination for both all-cause and cardiovascular mortality.
conclusionThe discrepancy between eGFRcys and eGFRcr levels is an independent predictor of all-cause mortality in a community-based Japanese population. eGFRdiff may serve as a simple yet informative marker for identifying individuals at increased risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.